JY
ARQT icon

Jeff Yass’s Arcutis Biotherapeutics ARQT Stock Holding History

Jeff Yass’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.76M Buy
219,815
+107,636
+96% +$2.51M ﹤0.01% 4334
2026
Q1 		$2.64M Buy
112,179
+103,312
+1,165% +$2.64M ﹤0.01% 5541
2025
Q4 		$257K Sell
8,867
-56,729
-86% -$1.45M ﹤0.01% 10306
2025
Q3 		$1.24M Sell
65,596
-195,391
-75% -$3.08M ﹤0.01% 6833
2025
Q2 		$3.66M Buy
260,987
+92,363
+55% +$1.29M ﹤0.01% 4567
2025
Q1 		$2.64M Buy
168,624
+104,523
+163% +$1.47M ﹤0.01% 4921
2024
Q4 		$893K Buy
64,101
+13,814
+27% +$151K ﹤0.01% 7250
2024
Q3 		$468K Sell
50,287
-4,396
-8% -$43.4K ﹤0.01% 8615
2024
Q2 		$509K Sell
54,683
-45,538
-45% -$412K ﹤0.01% 8225
2024
Q1 		$993K Sell
100,221
-228,656
-70% -$1.71M ﹤0.01% 6937
2023
Q4 		$1.06M Buy
328,877
+290,584
+759% +$790K ﹤0.01% 6851
2023
Q3 		$203K Buy
38,293
+23,412
+157% +$199K ﹤0.01% 10197
2023
Q2 		$142K Sell
14,881
-91,473
-86% -$1.02M ﹤0.01% 10629
2023
Q1 		$1.17M Buy
106,354
+84,052
+377% +$1.22M ﹤0.01% 6402
2022
Q4 		$330K Sell
22,302
-38,193
-63% -$667K ﹤0.01% 8863
2022
Q3 		$1.16M Buy
60,495
+25,814
+74% +$585K ﹤0.01% 6264
2022
Q2 		$739K Buy
34,681
+15,249
+78% +$313K ﹤0.01% 7271
2022
Q1 		$374K Sell
19,432
-2,935
-13% -$49.7K ﹤0.01% 9715
2021
Q4 		$464K Sell
22,367
-1,168
-5% -$23.2K ﹤0.01% 9402
2021
Q3 		$562K Buy
23,535
+4,945
+27% +$113K ﹤0.01% 9065
2021
Q2 		$507K Sell
18,590
-16,412
-47% -$462K ﹤0.01% 9561
2021
Q1 		$1.01M Buy
35,002
+23,828
+213% +$744K ﹤0.01% 7710
2020
Q4 		$314K Sell
11,174
-22,623
-67% -$554K ﹤0.01% 9164
2020
Q3 		$990K Buy
33,797
+22,205
+192% +$593K ﹤0.01% 6143
2020
Q2 		$351K Buy
+11,592
New +$335K ﹤0.01% 8070

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jeff Yass's ARQT Position: Q2 2026 in Review

Jeff Yass increased its Arcutis Biotherapeutics (ARQT) stake by 96% in Q2 2026, buying an estimated $2.51M and bringing the position to 219,815 shares worth $5.76M. The position accounts for ﹤0.01% of the portfolio, ranked #4334.

Jeff Yass first reported a position in ARQT in Q2 2020 and has held it in 25 quarters since. 271 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Jeff Yass held 219,815 shares of Arcutis Biotherapeutics worth $5.76M as of Q2 2026.
  • Jeff Yass bought 107,636 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.51M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4334 holding.
  • Jeff Yass first reported a position in Arcutis Biotherapeutics in Q2 2020 and has held it in 25 quarters since.
  • 271 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.